Ezmekly becomes first approved EU therapy for NF1-PN in children and adults - PharmaTimes EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics

#Merck #SpringWorksTherapeutics #Ezmekly #mirdametinib #NF1PN #plexiformneurofibromas #neurofibromatosistype1 #NF1 #NF1PNpatients #NationalReferenceCenterforAdultPatientswithNeurofibromatosis #phase2bclinicaltrial #ReNeutrial #NFpatients #RareTumors
pharmatimes.com/news/ezmekly...